The Glow Protocol
Protocol Overview
DURATION
8–12 weeks
PEPTIDES
2–3
PRIMARY GOAL
Skin Rejuvenation
INJECTIONS / DAY
1–2
Why These Peptides Work Together
- M-01
Collagen & Elastin
GHK-Cu directly stimulates fibroblasts to produce type I and III collagen, elastin, and glycosaminoglycans — the structural proteins of youthful skin.
- M-02
Inflammation Reduction
BPC-157 powerfully reduces inflammatory cytokines in skin tissue. Accelerates healing, reduces redness, calms rosacea and acne scarring.
- M-03
Angiogenesis
BPC-157 promotes new blood vessel formation, improving blood supply to skin tissue and accelerating nutrient delivery and waste removal.
- M-04
Matrix Remodeling
GHK-Cu activates matrix metalloproteinases that remove old, cross-linked collagen and replace it with fresh fibers — key to reducing scars and deep wrinkles.
Dosing Phases
Phase 01 — Loading (Weeks 1–4)
| Peptide | Dose | Frequency | Notes |
|---|---|---|---|
| GHK-Cu Injectable | 2–5mg | Daily or every other day | Subcutaneous near target areas (face, scalp) |
| BPC-157 | 250–500mcg | Daily | Subcutaneous — systemic or local |
Phase 02 — Maintenance (Week 5+)
| Peptide | Dose | Frequency | Notes |
|---|---|---|---|
| GHK-Cu Injectable | 2mg | 3× per week | Reduce frequency as skin improves |
| BPC-157 | 250mcg | 3× per week | Maintenance phase |
| GHK-Cu Topical | 0.5–1% | Twice daily (all phases) | Apply morning and evening |
Optional Add-On — TB-500
For users targeting wound healing, scarring, or systemic skin issues, adding TB-500 (Thymosin Beta-4) accelerates results. TB-500 promotes actin polymerization in cells — critical for tissue repair and wound healing.
DOSE
500mcg–2mg
FREQUENCY
2× weekly
DURATION
4–8 weeks
ROUTE
Subcutaneous
What to Expect
| Period | Expected Effect |
|---|---|
| Week 1–2 | BPC-157 begins reducing skin inflammation. Subtle brightness in tone. |
| Week 3–4 | GHK-Cu collagen stimulation apparent. Skin firmer, hydrated. Fine lines soften. |
| Week 5–8 | Most visible improvements. Scars flatten, wrinkles reduce, tone evens. |
| Week 9–12 | Consolidation. Transition to maintenance. New collagen matures. |
Tips for Best Results
- T-01Add topical GHK-Cu serum (0.5–1%) twice daily alongside injectable for surface and deep collagen support.
- T-02Add topical SNAP-8 to forehead and eye area to reduce expression wrinkles.
- T-03Sun protection (SPF 30+) is critical — UV disrupts active collagen synthesis.
- T-04Stay hydrated and maintain adequate protein intake.
- T-05Take photos at baseline, week 4, and week 8 to track progress objectively.
Manila skin reality
On the ground in the Philippines
Manila is a hard environment for skin. Year-round 30–34°C heat, humidity above 70 percent, UV index hitting 11+ at solar noon for most of the year, particulate pollution from EDSA traffic — the protocol above gets you to the starting line; the operational layer is what determines whether the eight-week before/after photos actually show what they should. Sun protection (T-03 in the tips above) is not a generic recommendation here. It is the limiting factor on results.
On the dermatology pairing: the eight-to-twelve-week window of the Glow protocol overlaps perfectly with Manila's established medical-aesthetic ecosystem. Belo Medical Group, The Aivee Institute, and the dermatology clinics at Makati Medical Center, St. Luke's BGC, and Asian Hospital all run combination protocols where peptide injections sit alongside microneedling, fractional laser, or PRP. The clinic-grade work accelerates the dermal turnover the GHK-Cu and BPC-157 are stimulating biochemically. Pricing for a six-session microneedling course in Makati or BGC runs roughly USD 800 to 1,200 — fraction of US clinic pricing for the same equipment.
On sourcing: GHK-Cu injectable, BPC-157, and TB-500 are not FDA Philippines registered and live in research-grade territory. Topical GHK-Cu serum at 0.5–1% is sold in Mercury Drug and Watsons under cosmetic-grade labels (the percentage is rarely verified — most local cosmetic GHK-Cu serums are well under 0.5%) — for actual protocol-grade topical concentration, source from a research-peptide supplier or a Makati compounding pharmacy. SPF: every Filipino dermatologist I've spoken to recommends a Korean or Japanese tinted sunscreen at SPF 50+ over the typical US chemical sunscreens — Anessa, Biore UV Aqua Rich, Beauty of Joseon. Mercury Drug stocks all three.
January through April 2026
My 12-week run
I ran the loading + maintenance schedule from January 8, 2026 through April 2, 2026 — twelve weeks. GHK-Cu injectable 3mg subQ near the temples and forehead five days a week for the first four weeks, BPC-157 250mcg subQ in the abdomen daily for the same window. Topical GHK-Cu serum at roughly 0.8% concentration applied morning and evening (sourced from a compounding pharmacy in Salcedo Village in Makati for USD 38 per 30mL bottle — Mercury Drug stocks 0.5% serums but the labeling is unverified).
Photos at week 0, week 4, week 8, week 12 — same lighting, same condo bathroom in BGC, same time of day. By week 4 the redness from a decade of late-twenties Texas sun damage had visibly calmed. By week 8 a horizontal forehead line that had been deepening for two years had softened — not gone, softened. By week 12 the under-eye area was the most-changed region: less hollow, less dark. My partner noticed at week 6 unprompted, which I count as the legitimate signal.
One operational lesson: I underestimated the SPF requirement. Week 5 I spent a Saturday at the beach in Batangas without reapplying my sunscreen properly, came home with a mild burn across the cheekbones. Skin texture in that zone regressed by what I'd guess was two weeks of progress. I switched to Anessa SPF 50+ from the Mercury Drug at SM Aura the next week and didn't make that mistake again. UV is the ceiling on this protocol in PH — full stop.
What this protocol doesn't replace
Risks & honest disclaimer
This is editorial commentary, not medical advice. GHK-Cu, BPC-157, and TB-500 are not FDA Philippines registered for cosmetic or therapeutic use. They live in research-grade territory and personal use is undertaken at your own risk.
Documented risks: GHK-Cu can cause local injection-site reactions (redness, mild swelling, occasional bruising). BPC-157 is generally well-tolerated in the published preclinical record but human pharmacovigilance data is limited. TB-500 has been associated theoretically with concerns around angiogenesis in the context of existing malignancy — the evidence is weak but it's the reason the World Anti-Doping Agency banned it for athletes.
Do not run this protocol if you have an active malignancy, are pregnant or breastfeeding, have an active infection at the injection site, or have known allergies to copper compounds. If you have a personal or family history of melanoma, consult dermatology before starting GHK-Cu. Get baseline bloodwork (CBC, CMP, lipid panel) before week 0 and again at week 12 — Hi-Precision in Makati or BGC, USD 80–120 per panel.
Primary literature on the stack
Sources
- SRC-01Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018;19(7):1987. DOI: 10.3390/ijms19071987 · PubMed: 29986520 — comprehensive review of GHK-Cu mechanisms in collagen synthesis, anti-inflammatory action, and wound healing.
- SRC-02Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International 2015;2015:648108. DOI: 10.1155/2015/648108 · PubMed: 26236708 — fibroblast stimulation, MMP regulation, and matrix remodeling evidence.
- SRC-03Sikiric P et al. Stable gastric pentadecapeptide BPC 157, Robert's stomach cytoprotection / adaptive cytoprotection / organoprotection, and Selye's stress coping response. Inflammopharmacology 2018;26(4):917–947. DOI: 10.1007/s10787-018-0497-6 · PubMed: 29804166 — foundational mechanism review for BPC-157 anti-inflammatory and angiogenic action.
- SRC-04Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012;12(1):37–51. DOI: 10.1517/14712598.2012.634793 · PubMed: 22074294 — TB-500/Thymosin β4 mechanism of action in tissue repair.
- SRC-05FDA Philippines Verification Portal. verification.fda.gov.ph — confirms GHK-Cu, BPC-157, and TB-500 are not FDA PH registered.